Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 66pembrolizumab 48Fluorouracil 44Capecitabine 39Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 21Docetaxel 19Cisplatin 18S 1 (combination) 17Bevacizumab 15Drug Therapy 14Ramucirumab 13Irinotecan 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10sintilimab 9Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8atezolizumab 8Specimen Handling 8Biopsy 8durvalumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × IL32 protein, human × 1 year × Clear all
NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Case Comprehensive Cancer Center

Phase 1 Suspended
12 enrolled
GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡